Detection of Human Immunodeficiency Virus Type 1 (HIV-1) in Vaginocervical Secretions: Correlation With Clinical Status, Virologic and Immunologic Parameters, and the Presence of Other Infections

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Keywords

ClinConnect Summary

Predictors for the development of the acquired immunodeficiency syndrome (AIDS) in HIV infected individuals have been studied primarily among adult males and in selected small populations. Although many of these predictors may be relevant to women, HIV infection does manifest itself differently between the sexes. Therefore, it is important to study the spectrum of HIV disease in women and to identify unique and common markers, cofactors, and predictors of disease progression.

Part 009: HIV-infected female adults, independent of CD4+ cell count, will provide blood and VCS specimens obtained...

Gender

FEMALE

Eligibility criteria

• • Inclusion Criteria
• Patients must have:
• • Premenopausal status.
• • Intact uterus and cervix.
• • Documented HIV infection.
• • Current enrollment in a multisite longitudinal study, Women's Interagency HIV Study (WIHS).
• Required:
• • Stable or no antiretroviral therapy within 1 month prior to study entry.
• • Exclusion Criteria
• Concurrent Medication:
• Excluded:
• • Antifungal or antimicrobial medication in the vagina.
• Prior Medication:
• Excluded:
• • Antimicrobial or antifungal medications during the 48 hours prior to study entry.
• • Use of spermicide or douche in the 48 hours prior to entry.
• • Coital interaction during the 48 hours prior to study visit, as reported by subject and confirmed by a negative seminal fluid assay result.